RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling
pathway inhibitor RO4929097 (RO4929097) and erlotinib hydrochloride when given together in
treating patients with non-small cell lung cancer that is stage IV or has come back.
RO4929097 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.